web statistics
AboutOur TechnologyCore AreasInvestor Relations & NewsPartneringContact
KineMed  ► Core Areas > Cancer

Predicting Clinical Progression in Cancer

Key Capabilities

Though a comprehensive survey of the deregulated cancer proteome, our tests can identify novel signatures of tumor aggressiveness in CLL in order to identify better which patients will benefit from treatment. This information is critical for a determination by a physician when intervention with treatment is appropriate. This assay can be linked to a companion therapeutic and can determine whether the therapeutic will work for a particular patient and the appropriate time to commence treatment with a therapeutic or another form of treatment.

5980 Horton Street | Suite 470 | Emeryville, CA 94608 | Tel.: USA [1] 510.655.6525 | Fax: [1] 510.655.6506 | TOLL-FREE: 855.KINEMED 

 Copyright © 2014 KineMed, Inc.  |  All Rights Reserved  |  Privacy  |  Terms & Conditions